Lombard Odier Asset Management (Switzerland) Sa Arcus Biosciences, Inc. Transaction History

Lombard Odier Asset Management (Switzerland) Sa

$1.14 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $973,219 - $2.13 Million	-56,484 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $1.63 Million - $2.36 Million	56,484 New	56,484 $1.78 Million

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

Black Rock Inc. New York, NY

9.76M
Shares

$145 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.47M
Shares

$81.4 Million
0.0% of portfolio
Woodline Partners LP San Francisco, CA

3.48M
Shares

$51.8 Million
0.48% of portfolio
State Street Corp Boston, MA

3.01M
Shares

$44.8 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

2.44M
Shares

$36.3 Million
0.1% of portfolio

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.07B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Switzerland) Sa, based on Form 13F filings with the SEC.

News

Stay updated on Lombard Odier Asset Management (Switzerland) Sa with notifications on news.

Account